Glycolipids in GBS: from basic science to clinical interface

Meehan, G. (2016) Glycolipids in GBS: from basic science to clinical interface. In: Willison, H. J. and Goodfellow, J. (eds.) GBS100: Celebrating a Century of Progress in Guillain-Barré Syndrome. Peripheral Nerve Society: San Diego, CA, pp. 327-333. ISBN 9780997510300

Full text not currently available from Enlighten.


In the 100 years since GBS was first described, GBS research has advanced significantly from basic electrophysiology studies to the identification of the pathological pathways involved in the onset of the disease. Arguably, one of the most important discoveries in the history of GBS was the association of the condition with anti-ganglioside antibodies. These antibodies are able to elicit injury by targeting gangliosides in the peripheral nerves and have become a major focus of current research—but what of the gangliosides themselves? Since their discovery in the late 1930s, these cell surface receptors have been shown to be essential components of not only the nervous system, but also of almost all cells and tissues of the body. This Top 10, therefore, focuses on establishing the major milestones in ganglioside research, with a particular emphasis on their impact on the study of GBS.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Meehan, Dr Gavin
Authors: Meehan, G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Publisher:Peripheral Nerve Society
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record